Table 6.
ASTRO and GEC-ESTRO suitable patient recommendation selections for APBI outside of clinical trials
| Suitable group by ASTRO [138] | Low Risk group by GEC-ESTRO [137] | |
|---|---|---|
| Factors | Criterion | Criterion |
| Age | > 60 y | > 50 |
| BRCA 1, 2 Mutation | Not present | na |
| Tumor Size | < 2 cm | < 3 cm |
| T stage | T1 | T1-2 |
| Margins | Negative by at least 2 mm | Negative by at least 2 mm |
| Grade | any | any |
| LVSI | Not allowed | Not allowed |
| ER status | positive | any |
| Multicentricity | unicentric | unicentric |
| Multifocality | Unifocal with total size of < 2 cm | unifocal |
| Histology | IDC, mucinous, tubular and colloid | IDC, mucinous, medullary, colloid |
| DCIS | Not allowed | Not allowed |
| EIC | Not allowed | Not allowed |
| Associated LCIS | Allowed | Allowed |
| Nodal status | pN0 (by SN Bx or ALND | pN0 (by SLNB or ALND) |
| Neoadjuvant Therapy | Not allowed | Not allowed |
APBI = accelerated partial breast irradiation, IDC = invasive ductal carcinoma, ILC = invasive lobular carcinoma, LCIS = lobular carcinoma in situ; DCIS = ductal carcinoma in situ; EIC = extensive intraductal component; LVI = lympho-vascular invasion; ER = estrogen receptor; SLNB = sentinel lymph node biopsy; ALND = axillary lymph node dissection